EyePoint's drug for age-related eye disease fails late-stage trial, shares tank

EyePoint's experimental drug Duravyu for wet age-related macular degeneration failed its primary efficacy endpoint in a late-stage trial, causing a share price drop of over 70%. The drug's approval depends on a second trial expected later this year, with the company aiming for FDA approval in early 2027.

This Wire brief sits within Fusion42's coverage of Medtech.